NCT02611063View on ClinicalTrials.gov

Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

February 28, 2021

Study Completion Date

February 22, 2022

Conditions
Hematological Malignancies
Interventions
DRUG

fostamatinib

100mg qd, 150mg qd, or 100mg bid

Trial Locations (1)

27710

Duke University of Medicine, Durham

All Listed Sponsors
lead

Stefanie Sarantopoulos, MD, PhD.

OTHER

NCT02611063 - Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant | Biotech Hunter | Biotech Hunter